China-based Hebei Viroad Biotechnology has invested €5m ($7m) in Gilupi, a Germany-based drugs developer, as part of a wider licensing agreement”for large parts of Asia”.

Gilupi raised €3.6m in its series C round in January 2011.

Previous investors include state- and corporate-backed early-stage investment manager High-Tech Gründerfonds (HTGF) and regional banks and state funds Aurelia Technologie-Fonds I, KfW and BC Brandenburg Capital and sparkassen of the state of Brandenburg (S-UBG).

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?